Overexpression of sigma receptors in nonneural human tumors.
Previous data indicated that opioid receptors occur in both neural and nonneural human tumors. However, it has recently been shown that some of the putative opioid binding may be attributable to sigma sites. In this study the occurrence of sigma and opioid receptors in nonneural human tumors was assessed. The neoplasms included renal and colon carcinomas and a sarcoma. [3H]1,3-di-o-tolylguanidine was used to assay sigma receptors by homologous competition binding assays, which when analyzed provided dissociation constant and receptor density values. Opioid binding was measured with [3H]-(-)-ethylketocyclazocine, a ligand which interacts with mu, delta, and kappa subtypes. Fresh surgical specimens were obtained from 9 human neoplasms, selected for their large size, and compared with nonmalignant tissues. All 9 tumors contained sigma sites, and dissociation constant values were within the range of 27-83 nM. Occasionally, two-site fit the data better than one-site binding, suggesting the presence of multiple sigma sites. Opioid binding was not detected. Intratumoral variability was evaluated by sampling several locations on the periphery of the mass and one in the center. Each of the samples was bisected, with a portion reserved for histological examination to correlate morphological features with receptor data. Changes in sigma binding were not associated with the extent of fibrosis, viability, or necrosis. Receptor density values displayed moderate intra- and intertumoral variation (coefficients of variation, 8-39 and 27-49%, respectively). More important, sigma binding in tumors was found to be greater than or equal to 2-fold higher than that of control nonmalignant tissue.
Bem
W T
WT
Department of Surgery, St. Louis University, Missouri 63110-0250.
Thomas
G E
GE
Mamone
J Y
JY
Homan
S M
SM
Levy
B K
BK
Johnson
F E
FE
Coscia
C J
CJ
D001667:Binding, Competitive; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology; D006146:Guanidines / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology; D010880:Piperidines / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism*; D017480:Receptors, sigma; D012509:Sarcoma / Q000378:metabolism / Q000473:pathology
D006146:Guanidines; D010880:Piperidines; D011957:Receptors, Opioid; D017480:Receptors, sigma; C026539:preclamol; C050232:1,3-ditolylguanidine